532 related articles for article (PubMed ID: 12637112)
1. Weight management and current options in pharmacotherapy: orlistat and sibutramine.
Leung WY; Thomas GN; Chan JC; Tomlinson B
Clin Ther; 2003 Jan; 25(1):58-80. PubMed ID: 12637112
[TBL] [Abstract][Full Text] [Related]
2. [Pharmacological therapy of obesity].
Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
[TBL] [Abstract][Full Text] [Related]
3. Long-term pharmacotherapy for obesity and overweight.
Padwal R; Li SK; Lau DC
Cochrane Database Syst Rev; 2003; (4):CD004094. PubMed ID: 14584004
[TBL] [Abstract][Full Text] [Related]
4. Long-term pharmacotherapy for obesity and overweight.
Padwal R; Li SK; Lau DC
Cochrane Database Syst Rev; 2004; 2003(3):CD004094. PubMed ID: 15266516
[TBL] [Abstract][Full Text] [Related]
5. Systematic review of the clinical efficacy of sibutramine and orlistat in weigth loss, quality of life and its adverse effects in obese adolescents.
García Díaz E; Martín Folgueras T
Nutr Hosp; 2011; 26(3):451-7. PubMed ID: 21892560
[TBL] [Abstract][Full Text] [Related]
6. Long-term effects of weight-reducing drugs in people with hypertension.
Siebenhofer A; Jeitler K; Horvath K; Berghold A; Posch N; Meschik J; Semlitsch T
Cochrane Database Syst Rev; 2016 Mar; 3():CD007654. PubMed ID: 26934640
[TBL] [Abstract][Full Text] [Related]
7. Long-term changes in blood pressure following orlistat and sibutramine treatment: a meta-analysis.
Johansson K; Sundström J; Neovius K; Rössner S; Neovius M
Obes Rev; 2010 Nov; 11(11):777-91. PubMed ID: 20025693
[TBL] [Abstract][Full Text] [Related]
8. Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients.
Derosa G; Cicero AF; Murdolo G; Ciccarelli L; Fogari R
Diabetes Nutr Metab; 2004 Aug; 17(4):222-9. PubMed ID: 15575343
[TBL] [Abstract][Full Text] [Related]
9. Long-term effects of weight-reducing drugs in hypertensive patients.
Siebenhofer A; Horvath K; Jeitler K; Berghold A; Stich AK; Matyas E; Pignitter N; Siering U
Cochrane Database Syst Rev; 2009 Jul; (3):CD007654. PubMed ID: 19588440
[TBL] [Abstract][Full Text] [Related]
10. [How safe are the new obesity drugs? Indications and contraindications of orlistat and sibutramine].
Richter WO
MMW Fortschr Med; 1999 Dec; 141(49-50):32-6. PubMed ID: 10726144
[TBL] [Abstract][Full Text] [Related]
11. NPY5R antagonism does not augment the weight loss efficacy of orlistat or sibutramine.
Erondu N; Addy C; Lu K; Mallick M; Musser B; Gantz I; Proietto J; Astrup A; Toubro S; Rissannen AM; Tonstad S; Haynes WG; Gottesdiener KM; Kaufman KD; Amatruda JM; Heymsfield SB
Obesity (Silver Spring); 2007 Aug; 15(8):2027-42. PubMed ID: 17712121
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity.
Gokcel A; Gumurdulu Y; Karakose H; Melek Ertorer E; Tanaci N; BascilTutuncu N; Guvener N
Diabetes Obes Metab; 2002 Jan; 4(1):49-55. PubMed ID: 11874442
[TBL] [Abstract][Full Text] [Related]
13. Long-term effects of weight-reducing drugs in hypertensive patients.
Siebenhofer A; Jeitler K; Horvath K; Berghold A; Siering U; Semlitsch T
Cochrane Database Syst Rev; 2013 Mar; (3):CD007654. PubMed ID: 23543553
[TBL] [Abstract][Full Text] [Related]
14. Orlistat and sibutramine beyond weight loss.
Mannucci E; Dicembrini I; Rotella F; Rotella CM
Nutr Metab Cardiovasc Dis; 2008 Jun; 18(5):342-8. PubMed ID: 17928208
[TBL] [Abstract][Full Text] [Related]
15. Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus.
Norris SL; Zhang X; Avenell A; Gregg E; Schmid CH; Lau J
Cochrane Database Syst Rev; 2005 Jan; 2005(1):CD004096. PubMed ID: 15674929
[TBL] [Abstract][Full Text] [Related]
16. Currently available drugs for the treatment of obesity: Sibutramine and orlistat.
Chaput JP; St-Pierre S; Tremblay A
Mini Rev Med Chem; 2007 Jan; 7(1):3-10. PubMed ID: 17266632
[TBL] [Abstract][Full Text] [Related]
17. Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta-analysis.
Johansson K; Neovius K; DeSantis SM; Rössner S; Neovius M
Obes Rev; 2009 Sep; 10(5):564-75. PubMed ID: 19460116
[TBL] [Abstract][Full Text] [Related]
18. Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials.
Padwal R; Li SK; Lau DC
Int J Obes Relat Metab Disord; 2003 Dec; 27(12):1437-46. PubMed ID: 12975638
[TBL] [Abstract][Full Text] [Related]
19. Drug treatments for obesity: orlistat, sibutramine, and rimonabant.
Padwal RS; Majumdar SR
Lancet; 2007 Jan; 369(9555):71-7. PubMed ID: 17208644
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological management of obesity.
Hanif MW; Kumar S
Expert Opin Pharmacother; 2002 Dec; 3(12):1711-8. PubMed ID: 12472368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]